Identification of Dysregulated microRNAs in Glioma Using RNA-sequencing
- PMID: 33877554
- DOI: 10.1007/s11596-021-2355-9
Identification of Dysregulated microRNAs in Glioma Using RNA-sequencing
Abstract
Glioma is the most common malignant brain tumor in central nervous system. Despite advances in the treatment of glioma such as surgery and chemoradiotherapy, most patients are easy to relapse, resulting in adverse clinical outcomes. Hence, effective molecular-targeting treatment may be one of attractive strategies for glioma therapy. The dysregulated microRNAs (miRNAs), one of the candidates of therapeutic targets, are believed to play an important role in the progression of glioma. In this study, we aimed to examine the expression profile of miRNAs in glioma and provide a reference for glioma therapy. Firstly, expression profile of miRNAs in 5 normal brain tissues, 5 low-grade glioma (LGG) tissues and 5 glioblastoma (GBM) tissues was detected by RNA sequencing (RNA-seq). Next, the target genes of differentially expressed miRNAs (DEmiRNAs) were predicted and then GO enrichment and KEGG pathway analysis performed by bioinformatics. Finally, 10 miRNAs which were significantly up- or down-regulated both in GBM and LGG were validated by real-time quantitative PCR (qRT-PCR). RNA-seq results indicated a number of DEmiRNAs in glioma. There were 64 up-regulated miRNAs and 17 down-regulated miRNAs in LGG, and 181 up-regulated miRNAs and 124 down-regulated miRNAs in GBM, respectively. Bioinformatics analysis showed that the target genes of these DEmiRNAs were enriched in various biological processes and signaling pathways such as cell metabolic and developmental process. Selected DEmiRNAs were further confirmed by qRT-PCR. miRNA-10b-5p, miRNA-92b-3p and miRNA-455-5p were significantly up-regulated in both GBM and LGG; while miRNA-542-3p was significantly up-regulated in LGG; miRNA-184 and miRNA-206 were significantly down-regulated in both GBM and LGG; miRNA-766-5p and miRNA-1-3p were significantly down-regulated in GBM. The subject of our study demonstrated several dysregulated miRNAs may serve as a potential therapeutic target for glioma.
Keywords: RNA-sequencing; glioma; microRNA.
Similar articles
-
Microrna-1224-5p Is a Potential Prognostic and Therapeutic Biomarker in Glioblastoma: Integrating Bioinformatics and Clinical Analyses.Curr Med Sci. 2022 Jun;42(3):584-596. doi: 10.1007/s11596-022-2593-5. Epub 2022 Jun 8. Curr Med Sci. 2022. PMID: 35678909
-
miRNA-seq analysis of human vertebrae provides insight into the mechanism underlying GIOP.Bone. 2019 Mar;120:371-386. doi: 10.1016/j.bone.2018.11.013. Epub 2018 Nov 29. Bone. 2019. PMID: 30503955
-
Hypoxic signature of microRNAs in glioblastoma: insights from small RNA deep sequencing.BMC Genomics. 2014 Aug 17;15(1):686. doi: 10.1186/1471-2164-15-686. BMC Genomics. 2014. PMID: 25129238 Free PMC article.
-
Regulatory interplay between microRNAs and WNT pathway in glioma.Biomed Pharmacother. 2021 Nov;143:112187. doi: 10.1016/j.biopha.2021.112187. Epub 2021 Sep 21. Biomed Pharmacother. 2021. PMID: 34560532 Review.
-
Natural products in suppressing glioma progression: A focus on the role of microRNAs.Phytother Res. 2022 Apr;36(4):1576-1599. doi: 10.1002/ptr.7414. Epub 2022 Feb 16. Phytother Res. 2022. PMID: 35174549 Review.
Cited by
-
Regulation of a novel circATP8B4/miR-31-5p/nestin ceRNA crosstalk in proliferation, motility, invasion and radiosensitivity of human glioma cells.J Radiat Res. 2024 Dec 3;65(6):752-764. doi: 10.1093/jrr/rrae064. J Radiat Res. 2024. PMID: 39287101 Free PMC article.
-
Knockdown of hsa_circ_0008922 inhibits the progression of glioma.PeerJ. 2022 Dec 20;10:e14552. doi: 10.7717/peerj.14552. eCollection 2022. PeerJ. 2022. PMID: 36570001 Free PMC article.
-
Microrna-1224-5p Is a Potential Prognostic and Therapeutic Biomarker in Glioblastoma: Integrating Bioinformatics and Clinical Analyses.Curr Med Sci. 2022 Jun;42(3):584-596. doi: 10.1007/s11596-022-2593-5. Epub 2022 Jun 8. Curr Med Sci. 2022. PMID: 35678909
-
The Clinical Role of miRNAs in the Development and Treatment of Glioblastoma.Int J Mol Sci. 2025 Mar 18;26(6):2723. doi: 10.3390/ijms26062723. Int J Mol Sci. 2025. PMID: 40141375 Free PMC article. Review.
References
-
- Ostrom QT, Gittleman H, Liao P, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol, 2017,19(suppl_5):v1–v88 - DOI
-
- Weller M, van den Bent M, Hopkins K, et al. European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol, 2014,15(9):e395–403 - DOI
-
- Claus EB, Walsh KM, Wiencke JK, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus, 2015,38(1):E6 - DOI
-
- Anestis DM, Tsitsopoulos PP, Ble CA, et al. Congenital Glioblastoma Multiforme: An Unusual and Challenging Tumor. Neuropediatrics, 2017,48(6):403–412 - DOI
-
- Duffau H. Les glioblastomes en 2017 [Glioblastoma in 2017]. Rev Infirm, 2017,66(228):16–18 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical